Zolacabtagene- Autoleucel

also known as CC 97540 · BMS-986353 · Zola-cel

Developed for: systemic lupus erythematosus · systemic sclerosis · anti-neutrophil cytoplasmic antibody-associated vasculitis · autoimmune hemolytic anemia · autoimmune thrombocytopenia · diffuse large B-cell lymphoma · idiopathic inflammatory myopathy · lupus nephritis
+4 more
· multiple sclerosis · myasthenia gravis · neuromyelitis optica spectrum disorder with anti-AQP4 antibodies · rheumatoid arthritis
Investigated by: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Bristol-Myers Squibb · Celgene Corporation · Bristol-Myers Squibb Services Unlimited Company · Juno Therapeutics, a Subsidiary of Celgene · Massachusetts General Hospital
+1 more
· University of Texas Southwestern Medical Center

Trials 8 · a red edge is where a trial was stopped

today NCT07573332 · Ph 1 NCT07603557 · Ph 2 NCT07335562 · Ph 3 NCT07388277 · Ph 1/2 NCT07015983 · Ph 2 NCT06220201 · Ph 1 NCT05869955 · Ph 1 NCT04231747 · Ph 1

2021202220232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT07573332	Sep 2026 → Aug 2030 expected	neuromyelitis optica spectrum disorder with anti-AQP4 antibodies	University of Texas Southwestern Medical Center	Not yet recruiting	No outcome recorded
Phase 1	NCT06220201	Mar 2024 → Jul 2027 expected	multiple sclerosis, myasthenia gravis	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Recruiting	No outcome recorded
Phase 1	NCT05869955	Sep 2023 → Aug 2028 expected	idiopathic inflammatory myopathy, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Recruiting	No outcome recorded
Phase 1	NCT04231747	May 2020 → Feb 2024	diffuse large B-cell lymphoma	Juno Therapeutics, a Subsidiary of Celgene	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT07388277	Jul 2026 → Dec 2028 expected	anti-neutrophil cytoplasmic antibody-associated vasculitis	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 22 trials
Phase 2	NCT07603557	Aug 2026 → May 2030 expected	autoimmune hemolytic anemia, autoimmune thrombocytopenia	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Not yet recruiting	No outcome recorded
Phase 2	NCT07015983	Jul 2025 → May 2028 expected	lupus nephritis, systemic lupus erythematosus	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Recruiting	No outcome recorded
Phase 31 trial
Phase 3	NCT07335562	Aug 2026 → Nov 2028 expected	systemic sclerosis	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Recruiting	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

Field	Value	Cited text
Known as	Zolacabtagene- Autoleucel	“BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells” NCT07335562 ↗
Known as	BMS-986353	“Receive CC-97540 (BMS-986353) as part of the study” NCT07573332 ↗ 2 NCT07335562 ↗ NCT07603557 ↗
Known as	CC 97540	“Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.” NCT04231747 ↗ 6 NCT06220201 ↗ NCT07573332 ↗ NCT07015983 ↗ NCT04231747 ↗ NCT05869955 ↗ NCT07388277 ↗
Known as	Zola-cel	“BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells” NCT07335562 ↗
Modality	Cell therapy	“CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells” NCT04231747 ↗
Route	Intravenous	“one dose of CC 97540 administered by intravenous (IV) injection” NCT04231747 ↗
Target	CD19	“CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells” NCT04231747 ↗